APOE genotype | ɛ22: 0.60 (0.29–1.27) | ɛ22: 0.89 (0.66–1.21) |
ɛ32: 0.80 (0.69–0.94) | ɛ32: 1.00 (0.93–1.08) |
ɛ33: 1.00 (Ref.) | ɛ33: 1.00 (Ref.) |
ɛ42: 1.34 (1.04–1.74) | ɛ43: 1.01 (0.95–1.06) |
ɛ43: 2.03 (1.85–2.23) | ɛ42: 1.17 (1.03–1.34) |
ɛ44: 5.77 (4.89–6.81) | ɛ44: 1.30 (1.15–1.48) |
|
Male sex | 0.62 (0.40–0.96) | 0.64 (0.57–0.73) |
|
Body mass index |
|
Lowest tertile (CCHS: < 23.3; CGPS: < 24.0) | 1.00 (Ref.) | 1.00 (Ref.) |
|
Middle tertile (CCHS: 23.3–26.8; CGPS: 24.0–27.4) | 0.97 (0.88–1.08) | 0.98 (0.93–1.04) |
|
Highest tertile (CCHS: > 26.8; CGPS: > 27.4) | 0.96 (0.86–1.07) | 1.04 (0.98–1.10) |
|
Hypertension* | 0.82 (0.74–0.91) | 1.17 (1.11–1.24) |
|
Diabetes mellitus† | 1.30 (1.09–1.55) | 1.02 (0.93–1.11) |
|
Smoking‡ | 1.68 (1.52–1.85) | 1.49 (1.41–1.57) |
|
Alcohol consumption§ | 1.00 (0.89–1.12) | 0.97 (0.92–1.03) |
|
Physical inactivity¶ | 1.16 (1.06–1.27) | 1.13 (1.08–1.18) |
|
Postmenopausal status and hormonal replacement therapy** |
|
Premenopausal | 1.00 (Ref.) | 1.00 (Ref.) |
|
Postmenopausal without hormonal replacement therapy | 0.65 (0.42–1.00) | 0.47 (0.42–0.54) |
|
Postmenopausal with hormonal replacement therapy | 0.72 (0.46–1.13) | 0.53 (0.46–0.62) |
|
Lipid-lowering therapy†† | 0.81 (0.71–0.93) | 2.25 (2.13–2.38) |
|
Education < 8 yr | 1.34 (1.23–1.47) | 1.02 (0.97–1.07) |
|
Atrial fibrillation‡‡ | – | 1.52 (1.44–1.61) |